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www.embomolmed.org EMBOMore than a decade ago, ‘plasticity’ suddenly became a ‘fashionable’ topic with
overemphasized implications for regenerative medicine. The concept of ‘plasticity’ ispported by old transplantation work, at least for embryonic cells, and metaplasia
classic example of plasticity observed in patients. Nevertheless, the publication
a series of papers showing rare conversion of a given cell type into another
related cell raised the possibility of using any unaffected tissue to create at will
w cells to replace a different failing tissue or organ. This resulted in disingenuous
erpretations and a reason not to fund anymore research on embryonic stem cells
c). Moreover, many papers on plasticity were difficult to reproduce and thus
estioned; raising issues about plasticity as a technical artefact or a consequence of
e spontaneous cells fusion. More recently, reprogramming adult differentiated
lls to a pluripotent state (iPS) became possible, and later, one type of differentiated
ll could be directly reprogrammed into another (e.g. fibroblasts into neurons)
thout reverting to pluripotency. Although the latter results from different and
re robust experimental protocols, these phenomena also exemplify ‘plasticity’. In
s review, we want to place ‘plasticity’ in a historical perspective still taking into
count ethical and political implications.Introduction
The last years have witnessed ground-
breaking results that have radically
changed established concepts in stem
cell biology, such as the irreversibility
of the differentiated state. This was
mainly due to the possibility of ‘repro-
gramming’ a differentiated cell into an
‘induced pluripotent stem cell’ (iPSc)
by transfer of few transcription factors.
iPS cells are similar to embryonic stem
cells (ESc), the only truly pluripotent
cells that have raised hopes for regen-
erative medicine and also heated
ethical debates because they are
derived from human embryos, a stepnow unnecessary with iPS. Indeed, older results obtained by
cell fusion or nuclear transfer had shown that reversion to an
undifferentiated state is possible, but the easy and direct
approach that generates iPS cells has somehow set a milestone






Mol Med 4, 353–361More recently, direct reprogramming from one to another
differentiated cell type without transit through an ‘undiffer-
entiated, pluripotent’ state has moved further the field toward
rapid and safer clinical translation, since this procedure would
eliminate the risk of teratoma that both iPSc and ESc may
generate in vivo.
While many excellent reviews cover these topics exhaus-
tively, here we aim to highlight the concept of ‘plasticity’, i.e. the
ability of a cell to change its fate in response to extra-cellular
signals. Plasticity, that could be redefined as ‘environmental or
extrinsic factor-mediated reprogramming’ at variance with the
‘transcriptional or intrinsic factor-mediated reprogramming’
mentioned above, is a complex concept often mudded by
technical artefacts. We aim to discuss ‘plasticity’ in relation to
the above topics and also to older concepts such as trans-
determination, trans-differentiation and metaplasia. We aim to
create a unifying scenario that may allow placing old and newer 2012 EMBO Molecular Medicine 353
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354data under the same perspective and discuss the relative
implications for clinical translation that is already taking place
now.
Obviously it would be impossible and beyond our scope to
review such an enormous literature. Many excellent reviews on
specific topics exist, to which the reader is referred in the
subsequent sections. A few keystone observations will be
mentioned to create a historical frame indicating where various
events fit in the recent history of the field of plasticity.Cloning by nuclear transfer demonstrated that
adult nuclei can be reprogrammed
Many classical experiments of embryology had shown that cells
can change their fate when transplanted heterotopically (i.e. in
an anatomical location different from that which they had been
isolated from; see, e.g.: Gunhaga, 2011; Le Douarin et al, 2004).
However the generation of an adult frog from a nucleus
transplanted in the cytoplasm of an enucleated egg (Gurdon et
al, 1958), showed for the first time that the nucleus of a somatic
cell still contains all the information necessary and sufficient to
make another organism, and can be re-programmed by factors
that are present in the egg cytoplasm. Almost 40 years went by
before the same reprogramming could be demonstrated in a
mammalian nucleus that gave rise to the famous sheep ‘Dolly’
(Wilmut et al, 1997).Cell fusion and the discovery of MyoD
On a parallel route, cell fusion experiments showed that when
nuclei of two different tissues and species are artificially placedGlossary
Cell fusion
Is the phenomenon by which two cells fuse their membranes so that the
two nuclei end up in the same cytoplasm. It may occur naturally, e.g. in
skeletal myoblasts, or experimentally by exposing cells to fusogenic agents
like polyethylene glycol (PEG) or Sendai Virus.
Committed
Is used for progenitor cells that are fated to differentiate into a specific cell
type. Commitment can be divided in a reversible phase (which can still be
changed by external cues such as transplantation in a different anatomical
site) and an irreversible phase (which can no longer be modified).
Embryonic stem cells
Are isolated and expanded in vitro from mammalian blastocyst inner
cell mass (the internal part of the mammalian embryo before implantation
in the uterus, destined to form all the tissues of the future organism).
ES cells can be cultured indefinitely and maintain the ability to
differentiate into all cell types of the body either in vitro or after injection
into a blastocyst.
iPS cells
Induced pluripotent stem cells are cells (of any origin) that have been
reprogrammed by expression of few (usually 3 or 4) specific transcription
factors (e.g. c-Myc, Klf4, Oct4, Sox2) to an embryonic stage. The phenotype
 2012 EMBO Molecular Medicinein the same cytoplasm, often one predominates and activates the
genes of its own developmental program in the other nucleus
(Blau et al, 1983). This suggested that some transcription factor
might play a dominant role and impose its transcriptional
program. Myogenic determination gene (MyoD) was the first and
still most remarkable case of a single transcription factor that is
able to convert a non-myogenic cell into skeletal muscle (Davis
et al, 1987). Subsequent work by several laboratories showed that
cells can be myogenically ‘converted’ (‘directly reprogrammed’
according to nowadays terminology) with a frequency that is
proportional to the lineage relationship of the converted cells with
skeletal myoblasts, i.e. high in paraxial mesoderm cells, lower in
ectoderm and endoderm derived cells, almost null in amniotic
cells. It was later recognized that each transcription factor works
in concert with many others, and their activity also depends on
the epigenetic landscape and interactions with other molecules
such as microRNAs. Thus, the microenvironment inside a
nucleus plays a major role in determining the frequency of
conversion/reprogramming. At that time in the late 80s, many
laboratories tried to find an equivalent of MyoD in other tissues.
With the exception of NeuroD (Lee et al, 1995), these early
attempts failed in most cases and remained largely unpublished.Embryonic stem cells and the discovery of
pluripotency
Approximately at the same time, the discovery of ESc
(Evans and Kaufman, 1981; Martin, 1981) opened previously
unimaginable scenarios for regenerative medicine. Explanting
mouse blastocysts in culture leads, under proper conditions, to
unlimited proliferation of cells of the blastocyst inner cell mass
that, strikingly, maintain the potency of generating all the cellsof reprogrammed cells is very similar, though not identical to that of
ES cells.
Plasticity
Is the phenomenon by which a cell (usually not terminally differentiated)
changes its phenotype in response to environmental signals. Trans-
differentiation is the phenomenon by which an already differentiated cell
changes its phenotype in response to environmental signals; metaplasia is
a form of trans-differentiation that occurs in pathological conditions where
usually epithelial cells adopt the phenotype of another epithelium. It is
often a pre-neoplastic lesion.
Potency
Is the ability of stem/progenitor cells to differentiate into one or more types
of differentiated cells. Specifically: totipotency indicates the ability to
differentiate into any type of cells of the body including foetal annexes;
pluripotency indicates the ability to differentiate into any type of cells of
the body except foetal annexes; multipotency indicates the ability to
differentiate into several type of cells of the body; unipotency indicates the
ability to differentiate into only one cell type.
Regeneration
Is the process by which a tissue restores its physiological homeostatic
condition. It often recapitulates many aspects of tissue histogenesis during
development. When regeneration fails, tissue is progressively replaced by
fat infiltration and fibrosis.
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be used to replace any lost or damaged tissue. Moreover, upon
injection into the blastocele of a foster blastocyst, they colonize
all tissues, including gonads and can thus produce gametes that
entirely originate from ESc. Thus, mating two chimaeras can
produce a normal fertile mouse, entirely derived from ES cells.
Such a discovery opened the possibility to create numberless
models of human diseases, and related mutant mouse strains by
manipulating the genome in ESc.
The first derivation of human ES cells (Thomson et al, 1998)
made this methodology ‘immediately’ translatable to patients.
Indeed, 13 years went by before FDA approved the first trial,
conducted by Geron Co. in patients with spinal cord lesions. Why
all these years? In our opinion, two main reasons delayed clinical
translation, one scientific and one ethical that turned political.
For what concerns science, the major and still partially
unsolved problem for regenerative medicine, is the need to
induce differentiation in 100% of the cell population and not in
99.99% of them. In fact, even very few undifferentiated cells
contaminating the ‘differentiated’ or ‘committed’ population,
will continue to proliferate and give rise to a teratoma.
Currently, extremely sophisticated cell separation techniques
(Tang et al, 2011) and the possibility of inserting suicide genes
only inducible in undifferentiated cells (Naujok et al, 2010) have
reduced this risk to the point of convincing the FDA to authorize
few ES cells-based human trials for spinal cord lesions and
Stargardt’s Macular Dystrophy (ClinicalTrials.Gov).Ethical issues
The ethical issue was more complex and still fuels heated and, in
our opinion, outdated debates. Since human ES cells are derived
from pre-implantation human embryos, they are considered
‘human beings’ by the Catholic Church, and therefore have
the same moral status of a ‘person’, as defined by several
constitutions such as those of US and Italy (Avila, 2001;
Mazzoni, 2002). Human blastocysts are either obtained from
supernumerary embryos after in vitro fertilization procedures
(but in this case they would be ‘non-self’ to the patient), or from
‘ad hoc’ created blastocysts after nuclear transfer of a patient
nucleus into an anucleated human oocyte. The Catholic Church
condemns both procedures, and this was reflected in restrictive
regulations and funding limitations in the US and several
European countries. It should be noted that the political
situation and the relative influence of the Catholic Church
resulted in extremely different attitudes and regulations of
human ESc research. Europe has yet to reach a consistent
legislation, and this is reflected in unclear and ambiguous
sentences that appear in EC calls related to this topic
(Ralston, M, Pew Forum on Religion & Public Life: ‘Stem Cell
Research Around the World’ http://pewforum.org/Science-and-
Bioethics/Stem-Cell-Research-Around-the-World.aspx). While
Germany, Austria, Italy, Finland, Greece, Ireland, Portugal
and the Netherlands prohibit or severely restrict the use of ES,
Sweden, UK and to various extent Belgium and France have
regulations that allow free research on ES though all essentiallywww.embomolmed.org EMBO Mol Med 4, 353–361ban reproductive cloning (i.e. the creation of a human being
from nuclear transfer). Research on human ESc and the
derivation of new cell lines from supernumerary human
embryos are strictly regulated Switzerland and, it is forbidden
to create embryos for the sole purpose of research. In October
2011, the European Court banned patents based on human ESc
(Callaway, 2011), thus causing problems to European countries
with respect to countries like China (Dennis, 2002), India, South
Korea or Israel, that essentially have no regulations or patent
restrictions. The situation in the US changed with the different
administrations and Obama, in 2009, removed the restriction of
federal funding on ES cell research imposed during Bush’s
presidency.
Despite this complex and problematic situation, we believe
that the further consolidation of iPSc or, later in time, of direct
reprogramming, will end this controversy.Reprogramming to an embryonic-like state or
directly to another mature cell
Almost 20 years after MyoD discovery, Takahashi and
Yamanaka showed that transduction of embryonic mouse
fibroblasts with four transcription factors now known as the
Yamanaka factors (Oct4, Klf4, cMyc and Sox2), reprograms
somatic cells into an embryonic-like state: ‘induced pluripotent
stem cells’ or iPS cells (Takahashi & Yamanaka, 2006; Fig 1).
This discovery (named by Science the discovery of the year
in 2007) set an historical milestone in the field and the
number of papers published yearly on the topic keeps
increasing exponentially (for recent reviews see: Hanna et al,
2010; Jopling et al, 2011; Wilmut et al, 2011; Yamanaka & Blau,
2010). The possibility of deriving patient-specific ES-like
cells that can be indefinitely expanded in vitro, genetically
corrected if needed, and then induced to differentiate into
the desired cell type, appeared as a real breakthrough over
previous reprogramming approaches based on nuclear
transfer; it is technically simpler and apparently bypasses the
ethical controversies and their political consequences described
above. For the sake of records, it should be mentioned that
several recent papers have challenged the complete equivalence
of iPS and ES cells (for a recent review see: Power & Rasko,
2011). Until now, the differences reported do not seem to have a
major impact on the possible future clinical use of these cells,
with the possible exception of immunogenicity (Zhao et al,
2011).
Moreover, the argument that the reprogrammed nucleus is
anyway ‘old’, i.e. has the same age of the patient, appears to be
at least disingenuous when compared to spared embryo derived
ES cells, which are ‘non-self’: a reprogrammed cell should be
compared to a nuclear-transferred ES cell that has exactly the
same age and ‘self-ness’. However, the efficiency of derivation
of pluripotent cells from somatic cells could be affected by
several factors, including genetic and epigenetic profiles that are
correlated to the senescence process (Banito et al, 2009). Only
time will tell whether iPS will replace ES cells, but in any case,














Figure 1. Cell reprogramming.
A. Nuclear transfer into an anucleated oocyte reprograms a somatic nucleus,
thus generating a blastocyst from which ES cells can be derived.
B. Cell fusion exposes two different nuclei to the same cytoplasm, and one
nucleus may impose its transcriptional program (red) over the other (blue).
C. Transfer of specific transcription factors may reprogram a somatic cell
(yellow) to a pluripotent (iPS) or to another differentiated cell type (red).
D. Transplantation of a genetically labeled (blue nucleus) differentiated cell
(red) to a different tissue (yellow) may activate that developmental
program in the transplanted cell.
356immense, since they led to a revolution in biology, and the same
iPS cells would have never been discovered without them.Direct reprogramming
Finally, in the last 2 years, several laboratories showed that
it is possible to directly reprogram an adult fibroblast to a
cardiomyocyte or a neuron (and even specific neural subtypes),
by forced expression of usually two or three transcription factors
(Efe et al, 2011; Ieda et al, 2010; Kim et al, 2011; Szabo et al,
2010; Vierbuchen et al, 2010). In some cases a fate switch among
related pancreatic epithelial cells has been induced by the forced
expression of three or even a single transcription factors
(Collombat et al, 2009; Zhou et al, 2008). In all cases, and
examples are accumulating at a weekly pace, cells repress
their own transcriptional program and activate the new one 2012 EMBO Molecular Medicinewithout transiting through an ES-like state. Although many
issues remain to be solved, e.g. frequency of complete terminal
differentiation into the desired cell type, these data appear to
move the field even further toward their safe use since the
tumorigenic risk, associated with ES/iPS cells, would not exist
anymore. Obviously, especially in the case of certain human
cells, the total number of cells that can be expanded in vitro
would return as a problem due to the limited proliferation
potency of human fibroblasts. Why earlier attempts (at the time
of MyoD discovery) at directly reprogramming fibroblasts into
other types of differentiated cells failed, and more recent, iPS
cell-boosted attempts succeed, is probably due to the major
advances in our understanding of the transcriptional machinery,
that took place in the last 20 years.Environmental reprogramming
Parallel to these events, and currently outdated by the
development of molecular approaches, a flurry of data
accumulated during decades of work showing that, following
transplantation, embryonic or even adult cells, may change their
fate and adopt that of the surrounding cells. Indeed, heterotopic
transplantation of a group of cells, naturally fated to give rise to
tissue A, into developing tissue B, is a classic assay for fate
determination in embryology. If cells maintain the A phenotype,
they are considered ‘determined’ or ‘committed’ to fate A,
whereas if they turn into tissue B, they are considered
‘undetermined’ and ready to be instructed by signals emanating
from the extra-cellular microenvironment. It is conceivable that
these signalling molecules may lead to the activation of the same
genes that, once transfected into adult fibroblasts in vitro,
‘reprogram’ them to the desired cell fate.
Despite the fact that the mammalian embryo is considered
to be ‘regulative’, it was generally assumed, at least until
Yamanaka’s work, that once committed, cells could only
progress towards their fixed differentiation pathway or die. Yet,
numerous examples of ‘spontaneous change of fate’ exist in the
old literature, but they are often linked to post-natal tissue
damage and regeneration. For example, retina regeneration
by pigment cells in amphibians is a classic case of trans-
differentiation (or ‘spontaneous reprogramming’) that only
occurs after tissue damage (Okada, 1980). On the other hand,
a spontaneous trans-differentiation from smooth to skeletal
muscle in the mouse oesophagus was reported in 1995
(Patapoutian et al, 1995) but later questioned based upon
lineage tracing studies (Rishniw et al, 2003).
The field was changed in 1998, by a paper showing that the
bone marrow of normal adult mice contains cells that can
participate in skeletal muscle regeneration and give rise to new
muscle fibre nuclei (Ferrari et al, 1998; Fig 2). Bone marrow-
derived muscle cells were very few (less than 1%) and were
easily detected in the host muscle despite their low frequency,
because they expressed a muscle-specific nuclear LacZ.
Unpredicted by the authors, this paper opened a Pandora’s
box, whose ethical and political consequences far exceeded the
relevance of the data reported. Within a few years, the literatureEMBO Mol Med 4, 353–361 www.embomolmed.org
Review









Pluripotent stem cells (iPS) Direct 
reprogramming
Reprogramming
Embryonic stem cells (ES)
Figure 2. Changing the model of cell determination and differentiation. Grey arrows indicate the ability of ES and iPS cells to give rise to germ and somatic
layers, that proceed (light blue arrows) towards their various differentiated tissues. Green arrows represent the possibility of reprogramming differentiated cells to
a pluripotent state or directly to a different differentiated cell type, independently from the germ layer of origin.was flooded with papers, often in high profile journals (e.g.
Bjornson et al, 1999; Krause et al, 2001; Lagasse et al, 2000; Orlic
et al, 2001), showing that many cells of adult tissues, when
transplanted in a different regenerating tissue, may give rise
to one or more cell types that are typical of that recipient
environment. Often, conclusions were based on double
fluorescence, where one cell would show a tracer of its origin
and an antigen typical of the tissue where it had been
transplanted. Nevertheless, these data suggested that it would
have been possible to isolate patient’s own cells from an
unaffected tissue, expand and, if needed, genetically correct
them for transplantation into the affected tissue or organ. It was
obvious that the frequency of these events was almost
invariably very low, far below the threshold of any possible
clinical efficacy. In addition, in some cases it was clearly
demonstrated that bone marrow-derived Purkinije neurons,
cardiomyocytes and hepatocytes were the result of cell fusion
rather than reprogramming (Alvarez-Dolado et al, 2003; Balsam
et al, 2004; Wang et al, 2003). Yet, the idea of using this form of
environmental ‘reprogramming’ for clinical future aims circu-
lated and was rapidly adopted by ethicists and politicians to
reach the conclusion that ESc work was not only morally
condemnable, but also useless.
As mentioned above, the Bush Administration prohibited any
NIH funded project to work with human ES cells derived after
year 2001. Also, several European countries made the life of
people working with ESc difficult, and the papers mentioned
above unwillingly put a potent political weapon in their hands
(see, e.g.: Marwick, 2001). It is ironic that one of the seniorwww.embomolmed.org EMBO Mol Med 4, 353–361authors of the original article was actively engaged with the
Italian Radical Party to defend the possibility of working with
human ES in Italy, by promoting a referendum to abolish a law
(no. 40) of February 2004 that practically, though not formally,
prohibited work on human ES cells in Italy, and also introduced
a number of illogical and unscientific restrictions that
fortunately were later abolished because they were found to
be unconstitutional.
The reaction of the ESc scientific community was prompt and
vibrant; it started by heavily criticizing most of these papers, by
implying that ‘plasticity’ was the consequence of immune
staining or tissue culture artefacts, and explaining that the ones
that were confirmed by other independent laboratories were
the result of spontaneous cell fusion, where, as described
above, one nucleus would impose its transcriptional program to
the other. This culminated in three papers published at the
same time and practically burying the field of environmental
reprogramming and plasticity (Terada et al, 2002; Wagers et al,
2002; Ying et al, 2002). The fact that spontaneous cell fusion is
the natural mechanism through which skeletal muscle forms in
vertebrates (Mintz & Baker, 1967) was not considered at that
time, even though it did explain, at least in part, the result of
bone marrow giving rise to skeletal muscle (Ferrari et al, 1998),
and later and unexpectedly, to Purkinjie cells (Weimann et al,
2003). Nevertheless, years went by and ‘plasticity’ was
considered a concept not supported by solid experimental
evidence. However, in recent years, several papers, scientifi-
cally unquestionable and in high profile journals, showed
that cells can be environmentally reprogrammed to a complete 2012 EMBO Molecular Medicine 357
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358and mature fate. For example, the group of G. Smith, showed
that both embryonic and adult neural stem cells can be
reprogrammed by the mammary gland microenvironment
where they give rise to chimaeric glands and progressively
lose their neuronal identity (Booth et al, 2008). Even more
strikingly, clonally expanded epithelial cells of both embryonic
and adult rodent thymus were reprogrammed to multipotent
hair follicle stem cells in vivo, as they were found able to give
rise to all skin lineages, i.e. hair follicle, epidermis and
sebaceous glands, upon serial transplantation. Moreover,
reprogrammed thymic cells re-isolated from the hair follicle,
were able, to a variable extent, to revert to their primitive fate
once transplanted back into the thymus (Bonfanti et al, 2010).
In all these examples the morphogenetic signalling that
drives cell fate switch and broaden potency of differentiated
or ‘committed’ cells remains to be elucidated. However, the
complexity at the basis of such events should stimulate instead
of discouraging deeper investigation into the molecular
mechanisms of environmental reprogramming. This may have
relevance not only for cell therapy but also for cancer. Indeed,
there is increasing evidence that specific microenvironments
such as skeletal muscle, mammary gland or neural crest can
inhibit tumorigenic fate and reprogram cancer cells to a
‘normal’ phenotype (Booth et al, 2011; Bussard et al, 2010;
Kasemeier-Kulesa et al, 2008; Parlakian et al, 2010). Other
examples keep accumulating, such as those showing extra-
cellular signals enhancing transcription factor-mediated repro-
gramming to iPS (Lluis et al, 2008) or to another differentiated
cell type (Aviv et al, 2009). The recent work of Blanpain and
colleagues describes the existence of distinct unipotent stem
cells that maintain different lineages of the mammary gland
(Van Keymeulen et al, 2011). Authors’ conclusions are in
contrast to previous evidence of multipotent epithelial stem cells
in the mammary gland and are explained by distinguishing
how cell potency is defined during physiological tissue
homeostasis versus injury or transplantation models that may
broaden their differentiation capacity. Also, pathological
conditions such as atherosclerosis induce smooth muscle cells
to differentiate into osteochondrogenic precursors and chon-
drocytes (Speer et al, 2009). Importantly, epithelial metaplasias
are conditions in which an epithelium adopts the phenotype
of another epithelium, for instance when tracheal stem cells
undergo squamous metaplasia in response to microenviron-
mental stress or, in the pancreas, when exocrine acinar cells
become endocrine islet cells. As emphasized by Tosh and
Slack (2002), understanding the molecular basis beyond the
tissue-type switching that occurs in metaplasias is important,
as it can improve our ability to reprogram stem cells for
therapeutic purposes. This may be complex as recent evidence
suggests that Barret’s metaplasia (a transition from esophageal
to intestinal epithelium) can be mimicked in p63 null mice
and may depend upon competitive survival of embryonic cells
in the adult tissue rather than from genetic lesions of adult
cells (Wang et al, 2011). Finally, it was also shown that physical
cues, such as substrate stiffness may, by themselves, direct
mesenchymal stem cell fate towards one or another differentia-
tion pathway (Engler et al, 2006). 2012 EMBO Molecular MedicineWhat is the difference between ‘direct,
i.e. intrinsic factor-mediated’ and ‘environmental,
i.e. extrinsic factor-mediated’ reprogramming’?
‘Plasticity’, defined as the ability of a cell to change its
phenotype in response to extra-cellular signals, has now
acquired a broad and ill-defined general meaning. It does not
literally correspond to ‘trans-differentiation’, because the latter
only refers to already differentiated cells that directly switch to
another differentiation program without regressing to an ES-like
state. Plasticity instead refers also to a still undifferentiated
but ‘committed’ cell, either embryonic or adult, that during
its pathway towards the expected terminal differentiation
can be diverted towards another type of terminal differentiation.
At first sight, it would appear that approaches such as cell
fusion, exposure to oocyte extract, and environmental cell
reprogramming may be outdated by the most direct transfer of
defined transcription factors.
However, in our opinion, reprogramming by extrinsic factors
maintains an important role in stem cell biology for three
main reasons. First, the mammalian body is composed of
thousands of different cell types and we currently have the
recipe to convert ‘fibroblasts’ or direct ES/iPSc towards a
specific terminally differentiated cell (e.g. a dopaminergic
neuron: Caiazzo et al, 2011) only in a handful of cases.
The ‘environmental’ approaches may still be invaluable to
identify extra-cellular signals and downstream transcription
factors that are required to obtain a functional beta or alpha cell
of pancreatic islets or a cone or a cell of the heart conduction
system. Second, evidence is accumulating that fusion may
occur in vivo in many tissues, resulting in cell reprogramming
and thus contributing to regeneration (Sanges et al, 2011).
Third and more importantly, environmental reprogramming
may mimic in vitro, or following experimental transplantation,
natural processes that occur in vivo, though likely at low
frequency, and may be needed to finely tune the amount of
progenitor cells that are distributed among neighbouring
developing tissues. In this regard, we showed in the past that,
upon transplantation, human pericytes from skeletal muscle
are recruited to a skeletal muscle fate rather than following
their default pathway, i.e. the formation of the smooth muscle
layers surrounding the endothelium of blood vessels (Dellavalle
et al, 2007). We now have evidence that pericytes sponta-
neously change their fate, contributing to up to 7% of
developing skeletal muscle fibres and 20% of their associated
satellite cells during unperturbed post-natal development of
the mouse (Dellavalle et al, 2011). This supports the hypothesis
that pericytes represent a resident progenitor of post-natal
tissues endowed with the potency to generate the differentiated
cell types of that specific tissue (Bianco et al, 2008). The
implications of this concept for regenerative medicine can be
already appreciated as a phase I/II clinical trial, based upon
transplantation of mesoangioblasts (the in vitro counterpart
of skeletal muscle pericytes) from HLA-identical donors, is
ongoing at San Raffaele Hospital in Milan. It is important that the
cells to be transplanted possess, as a natural developmental
option, the ability to give rise to the desired tissue, i.e. skeletalEMBO Mol Med 4, 353–361 www.embomolmed.org
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Pending issues
Efficient reprogramming: Efficiency is the challenge for the future,
both for iPSc and ‘direct, i.e. intrinsic factor-mediated’ or ‘environ-
mental, i.e. extrinsic factor-mediated’ reprogramming. This implies
that all the cells will need to be reprogrammed to the desired
phenotype, within a short period of time.
Safety issues: Safety is a consequence of efficiency. If all cells are
reprogrammed, then undifferentiated, potentially tumorigenic cells
will no longer be present in the cell population. Safety related to
insertional mutagenesis, is rather related to the risk that vectors
integrate in dangerous regions of the genome and is not discussed in
this review.
Age and rejuvenation: Another crucial issue for the future clinical
translation of these different reprogramming strategies is the age of
the organism from which cells are reprogrammed. If cells are ‘old’
and cannot be rejuvenated during reprogramming (i.e. by telomere
elongation) then also the ‘reprogrammed’ cells will remain as old as
the patient. In addition, progression of many diseases leads to tissue
alterations, such as fibrosis, that will hamper transplantation of any
cell, including reprogrammed ones.muscle in our case, at a frequency that might be clinically
relevant.
Although what we discussed here raises novel and extra-
ordinary possibilities for efficiently repairing tissues and organs
using the patients’ own cells, we should not underestimate the
importance of carefully designing both controls and protocols.
In fact, cell transplantation clinical trials have been conducted
in the past where skeletal muscle cells, once transplanted
into the infarcted heart, were able to survive, differentiate
and spontaneously contract but did not integrate electrically
within the surrounding myocardium. As a consequence severe
arrhythmias developed, in some cases with a fatal outcome
(Menasche, 2011). Thus, even if short-term safety and efficacy
can be assessed in pre-clinical models, the biological features of
‘the human cell’ as a medicinal product can only be definitively
assessed in patients, with unavoidable associated clinical risks.
In the case mentioned above, no arrhythmias had developed
in rodents or large animal models. In addition, careful analysis
of chromosome stability, growth factor dependence and
maintenance of full differentiation potency is particularly
important for cells that have to be expanded in culture prior
to transplantation. The capacity of cells to adapt from an in vitro
to an in vivo microenvironment where they need to perform like
host resident cells will be understood only disclosing the basis
of intrinsic and extrinsic cell plasticity. Indeed, complete
functional integration of transplanted cells may become the
major hurdle for those tissues where complex intercellular
interactions and communication are required for optimal
function, reiterating the importance of in depth knowledge of
the host microenvironment. Of notice, this consideration applies
to any kind of ‘reprogramming’ also if achieved by transfer of
transcription factors or cell fusion.Conclusion
Plasticity is not an artefact. It is likely a compensatory
mechanism by which developing or regenerating tissues
adjust their cell number. It is rare but important. It may occur
by cell fusion or environmental reprogramming that are
mimicked in the laboratory by transfer of nuclei or transcription
factors. The years to come will likely provide answers to
these intriguing issues that are crucial for the future of
regenerative medicine.Acknowledgements
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